Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo®
iTeos Therapeutics’ $120M offering: The immuno-oncology company is selling about 1.1 million shares for $17.50 apiece. RA Capital Management and Boxer Capital — both existing investors — are leading the financing. iTeos added that its Phase 2 test of belrestotug plus dostarlimab in metastatic PD-L1 high non-small cell lung cancer “exceeded pre-defined efficacy criteria” at an interim assessment. Its stock $ITOS was up about 40% on Friday morning. — Jaimy Lee & Ayisha Sharma
Xbrane provides reg update on FDA review of its ranibizumab biosimilar candidate
Xbrane and Stada have announced that the European Commission has granted marketing authorisation for biosimilar candidate, Ximluci – also known as ranibizumab – which also references Lucentis.
Bad Vilbel; Solna – 16 September 2022 – Partners STADA Arzneimittel AG and Xbrane Biopharma AB (Nasdaq Stockholm: XBRANE) announce that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Ximluci®, a biosimilar candidate referencing Lucentis® (ranibizumab).
Selexis and Generium shared that they have launched Genolar, a biosimilar for omalizumab (Xolair) on the Russian market for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria for patients aged 6 years and up.
CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Xbrane Biopharma AB (STO: XBRANE) today announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® (certolizumab pegol)1.
Xbrane Biopharma AB (publ) (”Xbrane” eller ”Bolaget”) (Nasdaq Stockholm: XBRANE), a leading biosimilar developer, has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with the continued development of Xdivane™, a biosimilar candidate referencing Opdivo®, this forms an oncology biosimilar portfolio addressing €23 billion of combined annual reference product sales. Due to the announcement, Xbrane will host a videoconference tomorrow Tuesday December 14th, 11.00-11.45, registration in the link below.